GSK plc
GSK37.430USD
-0.070-0.19%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
77.58BMarktkapitalisierung
23.79KGV TTM
mehr Informationen über GSK plc Unternehmen
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).
Unternehmensinformationen
Unternehmens-codeGSK
Name des UnternehmensGSK plc
IPO-datumMay 22, 1972
Gegründet am1999
CEOMs. Deborah Waterhouse
Anzahl der mitarbeiter68629
WertpapierartOrdinary Share
GeschäftsjahresendeMay 22
Addresse980 Great West Road
StadtBRENTFORD
BörseLondon Stock Exchange
LandUnited Kingdom
PostleitzahlTW8 9GS
Telefon442080475000
Websitehttps://www.gsk.com/
Unternehmens-codeGSK
IPO-datumMay 22, 1972
Gegründet am1999
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
644.04K
--
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
483.75K
+7.69%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
34.31K
+0.51%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Non-Executive Independent Director, Scientific and Medical Expert
Non-Executive Independent Director, Scientific and Medical Expert
15.98K
+0.14%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.45K
+1.07%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.05K
+0.96%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
644.04K
--
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
483.75K
+7.69%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
34.31K
+0.51%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Non-Executive Independent Director, Scientific and Medical Expert
Non-Executive Independent Director, Scientific and Medical Expert
15.98K
+0.14%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.45K
+1.07%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.05K
+0.96%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Respiratory
9.22B
22.99%
HIV
9.06B
22.59%
Shingles
4.30B
10.72%
Established Vaccines
4.27B
10.64%
Immuno-inflammation
4.21B
10.51%
Other
9.04B
22.54%
Nach RegionUSD
Name
Umsatz
Anteil
US
20.93B
52.22%
Rest of world
18.25B
45.53%
UK
904.53M
2.26%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Respiratory
9.22B
22.99%
HIV
9.06B
22.59%
Shingles
4.30B
10.72%
Established Vaccines
4.27B
10.64%
Immuno-inflammation
4.21B
10.51%
Other
9.04B
22.54%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
3.33%
Fidelity Management & Research Company LLC
2.13%
PRIMECAP Management Company
1.23%
Fisher Investments
0.92%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
91.66%
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
3.33%
Fidelity Management & Research Company LLC
2.13%
PRIMECAP Management Company
1.23%
Fisher Investments
0.92%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
91.66%
Art
Aktionäre
Anteil
Investment Advisor
8.78%
Investment Advisor/Hedge Fund
6.23%
Hedge Fund
0.93%
Research Firm
0.71%
Bank and Trust
0.09%
Individual Investor
0.06%
Pension Fund
0.06%
Insurance Company
0.06%
Family Office
0.02%
Other
83.06%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1444
354.89M
17.21%
+26.92M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
2023Q1
1546
281.08M
13.72%
-55.01M
2022Q4
1546
286.90M
13.32%
-22.15M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dodge & Cox
68.44M
3.32%
+353.75K
+0.52%
Dec 31, 2024
Fidelity Management & Research Company LLC
43.77M
2.12%
+18.14M
+70.76%
Dec 31, 2024
PRIMECAP Management Company
25.26M
1.22%
+10.41M
+70.07%
Dec 31, 2024
Fisher Investments
18.84M
0.91%
+259.87K
+1.40%
Dec 31, 2024
JTC Employer Solutions Trusteee Ltd
20.28M
0.98%
-202.40K
-0.99%
Dec 31, 2024
Fidelity Institutional Asset Management
9.05M
0.44%
+5.68M
+168.17%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
8.85M
0.43%
+1.77M
+25.04%
Dec 31, 2024
T. Rowe Price International Ltd
7.57M
0.37%
+35.11K
+0.47%
Dec 31, 2024
State Street Global Advisors (US)
7.03M
0.34%
+247.17K
+3.65%
Dec 31, 2024
UBS Financial Services, Inc.
6.34M
0.31%
+5.69M
+871.38%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
The Opal International Dividend Income ETF
6.71%
VanEck Pharmaceutical ETF
4.7%
Keating Active ETF
3.52%
Brandes International ETF
3.27%
Sound Equity Dividend Income ETF
3.17%
Altrius Global Dividend ETF
1.9%
Pacer Global Cash Cows Dividend ETF
1.87%
USCF Dividend Income Fund
1.59%
Fidelity Blue Chip Value ETF
1.4%
Fidelity Women's Leadership ETF
1.08%
Mehr Anzeigen
The Opal International Dividend Income ETF
Anteil6.71%
VanEck Pharmaceutical ETF
Anteil4.7%
Keating Active ETF
Anteil3.52%
Brandes International ETF
Anteil3.27%
Sound Equity Dividend Income ETF
Anteil3.17%
Altrius Global Dividend ETF
Anteil1.9%
Pacer Global Cash Cows Dividend ETF
Anteil1.87%
USCF Dividend Income Fund
Anteil1.59%
Fidelity Blue Chip Value ETF
Anteil1.4%
Fidelity Women's Leadership ETF
Anteil1.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
20.79B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 05, 2025
GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
Apr 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023
May 19, 2023
Jul 13, 2023
May 18, 2023
Feb 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Apr 13, 2023
Feb 23, 2023
Nov 02, 2022
GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022
Nov 18, 2022
Jan 12, 2023
Nov 17, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Datum
Art
Verhältnis
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4